ABSTRACT
A comparative pharmacological pilot study of the monthly injectable contraceptive CycloProvera was carried out in 11 women in four centres. There were no significant differences in the results between the centres except that the injection-bleeding interval appeared to be shorter in Swedish women than in those in Havana and Mexico. Medroxyprogesterone acetate was detectable in blood for 28 to 62 days after injection of CycloProvera and although follicular activity returned in less than 28 days after injection in many of the women, corpus luteum function was suppressed for at least seven weeks in all women. Most of the women retained a regular menstrual pattern; six of 33 cycles were amenorrhoeic. There was no significant change in any of the biochemical and haematological analyses.
Subject(s)
Contraceptive Agents, Female/pharmacology , Estradiol/analogs & derivatives , Medroxyprogesterone/analogs & derivatives , Adult , Biopsy , Contraceptives, Oral, Combined/administration & dosage , Contraceptives, Oral, Combined/pharmacology , Drug Administration Schedule , Drug Combinations , Endometrium/drug effects , Estradiol/administration & dosage , Estradiol/blood , Estradiol/pharmacology , Female , Humans , Injections, Intramuscular , Medroxyprogesterone/administration & dosage , Medroxyprogesterone/blood , Medroxyprogesterone/pharmacology , Medroxyprogesterone Acetate , Menstruation/drug effects , Ovarian Follicle/drug effects , Ovulation/drug effectsABSTRACT
Two groups of vasectomy patients were reviewed: 376 men operated upon between 1968 and 1971 and 608 between 1974 and 1978. Average age, length of marriage, and number of living children prior to vasectomy were greater in the first group (P less than 0.01). The results are compatible with the idea that couples are planning smaller families and turning increasingly to vasectomy as a reliable permanent birth control method immediately following the completion of their families.
